Thermo Fisher Scientific (TMO) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research lowered shares of Thermo Fisher Scientific (NYSE:TMO) from a hold rating to a sell rating in a research report sent to investors on Thursday morning.

According to Zacks, “Post a promising third-quarter 2017 performance we are encouraged by Thermo Fisher’s series of product launches along with progress in precision medicine initiatives. At the same time, we are upbeat about Thermo Fisher recently completing the acquisition of Phenom-World. Moreover, the newly-integrated FEI Company has already started to boost its analytical instruments arm. We are currently looking forward to Thermo Fisher gaining entry into the CDMO market through the recently-closed $7.2 billion acquisition of Patheon. The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through 2017. Unfavorable macroeconomic conditions continue to weigh heavily on Thermo Fisher's stocks. Over the past six months, Thermo Fisher is trading above the broader industry. On the flip side, competitive headwinds and rising operating costs continue to pose a threat on the stock's value.”

TMO has been the subject of several other reports. Jefferies Group reissued a hold rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Leerink Swann reissued an outperform rating and issued a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. BTIG Research began coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a buy rating and a $230.00 target price for the company. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a buy rating and a $225.00 price objective for the company. Finally, Evercore ISI began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an outperform rating and a $220.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $212.21.

Shares of Thermo Fisher Scientific (NYSE:TMO) opened at $210.17 on Thursday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The company has a market cap of $84,277.12, a P/E ratio of 35.68, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. Thermo Fisher Scientific has a 1 year low of $140.00 and a 1 year high of $211.54.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.03 earnings per share. sell-side analysts predict that Thermo Fisher Scientific will post 9.36 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at $58,016,113.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.49% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock valued at $4,640,970,000 after purchasing an additional 629,093 shares during the last quarter. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock valued at $4,074,828,000 after purchasing an additional 366,584 shares during the last quarter. Capital Research Global Investors raised its stake in Thermo Fisher Scientific by 29.8% during the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after purchasing an additional 3,973,136 shares during the last quarter. Capital World Investors raised its stake in Thermo Fisher Scientific by 6.1% during the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after purchasing an additional 671,637 shares during the last quarter. Finally, Longview Partners Guernsey LTD raised its stake in Thermo Fisher Scientific by 7.4% during the 3rd quarter. Longview Partners Guernsey LTD now owns 4,564,913 shares of the medical research company’s stock valued at $863,682,000 after purchasing an additional 313,782 shares during the last quarter. Hedge funds and other institutional investors own 86.22% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/15/thermo-fisher-scientific-tmo-downgraded-by-zacks-investment-research-to-sell.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply